<DOC>
	<DOCNO>NCT01757587</DOCNO>
	<brief_summary>The main objective show addition Galvus versus placebo patient type 2 diabetes treat metformin ( maximum tolerate dose ) basal insulin properly titrate , allow great proportion patient achieve HbA1c 7 % . The primary efficacy endpoint percentage patient respond treatment ( HbA1c less 7 % ) 3 month treatment Galvus placebo</brief_summary>
	<brief_title>Galvus ( Vildagliptin ) v Placebo Combination With Metformin Insulin</brief_title>
	<detailed_description>- Visit V1 : screen - Inclusion visit V2 : Be verify inclusion criterion patient . At inclusion visit collect : - Informed consent participate studyâ€¦ - The following data : age , duration diabetes , usual basal insulin dose , co-morbidities : hypertension , complication diabetes , dyslipidemia , smoking ( associated treatment ) . - Data physical examination particular : weight , BMI , waist circumference , systolic blood pressure ( SBP ) diastolic ( DBP ) - Therapeutic adjustment make . In case inefficient combination sulphonylurea ( HbA1c &gt; 7 % ) , stop basal insulin titrate run- period ( 2 month ) order obtain good control fast glucose . - Visit V3 : At randomization visit , collect result HbA1c biological assessment ( FPG , fast lipid profile ) . Moreover , insulin collect patient receive treatment 3 month ( ex Galvus case accord randomisation ) . - Visit V4a glycemic holter introduce remove 5 day later ( visit V4B ) . The interstitial glucose calibrate Holter blood glucose . When collect glycemic holter , patient also clinical examination new biological assessment ( HbA1c , FPG , C peptide , fast lipid ... ) assessment dietary intake port holter ( overall calorie intake : cal + G , L , P ) - Visit V5 : patient receive treatment 3 month ( placebo visit accord example cite ) . - Visit V6A , visit V4a , glycemic holter introduce remove V6B visit . Similarly , collection glycemic holter , patient also new clinical examination , laboratory evaluation ( HbA1c , FPG , fast lipid ... ) dietary assessment ( overall calorie intake : cal + G , L , P ) .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients treat least 3 month metformin ( maximum tolerate dose ( least 1 month ) + / sulfamide basal insulin Patient HbA1c 7 9 % inclusion visit Patients able use continuous glucose monitoring system , Patients already receive specific treatment postprandial ( GLP1 , .. ) Patients type 1 diabetes , secondary diabetes Patients eat disorder Patients major complication diabetes Patients participate another clinical trial Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Galvus</keyword>
	<keyword>basal insulin</keyword>
	<keyword>HbA1c</keyword>
</DOC>